Mgr. Marek Borský
Researcher, Department of Internal Medicine, Hematology and Oncology
Correspondence Address:
Jihlavská 340/20, 625 00 Brno
Phone: | +420 532 23 4830 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 115
2018
-
Inovativní inhibitor proteinu CHK1 indukuje apoptózu u buněk chronické lymfocytární leukémie s mutacemi v genu TP53
Year: 2018, type: Conference abstract
-
Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL
Leukemia, year: 2018, volume: 32, edition: 1, DOI
-
Promoter methylation of ROR1 ligand WNT5A associates with its expression in CLL
Year: 2018, type: Conference abstract
-
Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels
Leukemia, year: 2018, volume: 32, edition: 9, DOI
-
Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations
Year: 2018, type: Conference abstract
-
Uvolnění buněk chronické lymfocytární leukemie z lymfatického systému do periferie po aplikaci rituximabu
Year: 2018, type: Conference abstract
-
Vyplavení B lymfocytů z uzlin do periferie po podání rituximabu pacientům s CLL
Year: 2018, type:
2017
-
BCR signalling proficient chronic lymphocytic leukaemia cells are prone to rituximab mediated elimination in vivo.
Year: 2017, type: Conference abstract
-
Dopad rekurentních mutací na dobu do progrese po terapiích zahrnujících rituximab v 1. linii u pacientů s CLL.
Year: 2017, type: Conference abstract
-
Impact of recurrent mutations on progression-free survival in CLL patients treated with front line rituximab-based regimens.
Year: 2017, type: Conference abstract